Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Today, although the triple treatment with clarithromycin accepted as the primary treatment
for Helicobacter pylori infection eradication is well tolerated, the eradication has been
decreased to 65 %. However, the eradication resulting from TRIOL treatment with levofloxacin
is expected to be 75 % or higher. If the target results can be reached, it will be concluded
that TRIOL treatment with levofloxacin will be an alternative to the triple treatment with
clarithromycin as the primary treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Deva Holding A.S.
Collaborators:
TC Erciyes University TNC Ilac Arastirma Gelistirme Danismanlik San. ve Tic. Ltd. Sti.